ReviewCardiovascular drugs and therapy2022
Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.
Review in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 31 citations in OpenAlex.
- The prognostic value of combined TyG and SIRI categories for cardiovascular disease and all-cause mortality among adults: Evidence from the NHANES 1999-2010.American heart journal plus : cardiology research and practice · 2026Article
- Repurposing of colchicine: critical examination of clinical trials and scoping review.European journal of clinical pharmacology · 2026Article
- Effects of Early Treatment with Lipid Core Nanoparticles-Associated Methotrexate on Cardiac Remodeling and Soleus Muscle Inflammasomes in Infarcted Rats.International journal of molecular sciences · 2026Article
- Immune dysregulation complicated by recurrent in-stent restenosis in patients with multivessel coronary artery disease: a case report.BMC cardiovascular disorders · 2026Article
- Compound Danshen decoction identifies its mechanism of antagonizing atherosclerosis by network pharmacology and transcriptomics.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Causal Mediation of Immune Cells and Fatty Acids in Coronary Atherosclerosis: Insights From Mendelian Randomization Analysis.Human mutation · 2026Article
- The impact of metabolic syndrome and triglyceride-glucose index on the risk of in-stent restenosis after percutaneous coronary intervention: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- The Monocyte-to-Lymphocyte Ratio Exhibits A Superior Prognostic Value in Patients with Newly Diagnosed Acute Coronary Syndrome.Reviews in cardiovascular medicine · 2025Article
- The systemic inflammatory response index as a risk factor for all-cause and cardiovascular mortality among individuals with coronary artery disease: evidence from the cohort study of NHANES 1999-2018.Journal of geriatric cardiology : JGC · 2025Article
- Causal effects of circulating immune cells on coronary atherosclerosis: Evidence from Mendelian randomization.Medicine · 2025Article
- The Role of mtDNA Mutations in Atherosclerosis: The Influence of Mitochondrial Dysfunction on Macrophage Polarization.International journal of molecular sciences · 2025Review
- Cytokine and Oxidative Stress Imbalances in Relation to Complex Coronary Lesions in Elderly Patients.Current vascular pharmacology · 2025Article
- Laboratory-derived inflammatory ratios as a novel diagnostic model for premature coronary artery disease.Frontiers in endocrinology · 2025Article
- From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion.International journal of molecular sciences · 2024Review
- Circulating levels of C1q/TNF-α-related protein 6 (CTRP6) in coronary artery disease and its correlation with inflammatory markers.Journal of diabetes and metabolic disorders · 2024Article
- Tandem lesions associate with angiographic progression of coronary artery stenoses.International journal of cardiology. Heart & vasculature · 2024Article
- Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.International journal of molecular sciences · 2024Review
- Tea polyphenol-derived nanomedicine for targeted photothermal thrombolysis and inflammation suppression.Journal of nanobiotechnology · 2024Article
- Artificial intelligence-powered insights into high-risk, non-obstructive coronary atherosclerosis: a case report.European heart journal. Case reports · 2024Article
- Relationship between the lymphocyte to C‑reactive protein ratio and coronary artery disease severity.Experimental and therapeutic medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Atherosclerotic coronary artery disease has a complex pathogenesis which extends beyond cholesterol intimal infiltration. It involves chronic inflammation of the coronary artery wall driven by systemic and local activation of both the adaptive and innate immune systems, which can ultimately result in the rupture or erosion of atherosclerotic plaque, leading to thrombosis and myocardial infarction (MI). Despite current best practice care, including the widespread use of cholesterol-lowering statins, atherothrombotic cardiovascular events recur at alarming rates post-MI. To a large extent, this reflects residual inflammation that is not adequately controlled by contemporary treatment. Consequently, there has been increasing interest in the pharmacological targeting of inflammation to improve outcomes in atherosclerotic cardiovascular disease. This has comprised both novel pathway-specific agents, most notably the anti-interleukin-1 beta monoclonal antibody, canakinumab, and the repurposing of established, broad-acting drugs, such as colchicine, that are already approved for the management of other inflammatory conditions. Here we discuss the importance of inflammation in mediating atherosclerosis and its complications and provide a timely update on "new" and "old" anti-inflammatory therapies currently being investigated to target it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.